Indicated for: pulmonary arterial hypertension
Substance: treprostinil (antihypertensive)
ATC: B01AC21 (Blood and blood forming organs | Antithrombotic agents | Platelet aggregation inhibitors excl. heparin)
Treprostinil is a synthetic analog of prostacyclin used in the treatment of pulmonary arterial hypertension (PAH). It works by dilating blood vessels in the lungs and reducing pulmonary vascular resistance, thereby improving blood flow and exercise capacity in patients.
Treprostinil can be administered as an intravenous, subcutaneous, inhaled infusion, or oral tablets, depending on the severity of the disease and patient preferences. It is commonly used to alleviate symptoms such as shortness of breath, fatigue, and chest pain associated with PAH.
Common side effects include headache, nausea, diarrhea, pain at the injection site (for subcutaneous administration), and facial flushing. Careful monitoring is essential for dose adjustment and prevention of complications.
Treprostinil is an essential medication in managing pulmonary arterial hypertension, helping to improve quality of life and extend survival in patients.